Institute News
Most Popular
Free community webinar about MacTel
November 14, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database. Neurotech has partnered with Prevent Blindness to sponsor an online event with a focus on MacTel Type 2. This free webinar...
MacTel SAFE Study
March 6, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database. LMRI is conducting the SAFE study (Phase 2a Study of the Effect of Serine Supplementation and Fenofibrate Treatment on Serum...
Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)
LMRI would like to share the following press release from Neurotech Pharmaceuticals about the BLA for NT-501 as a treatement for MacTel: Cumberland, R.I., November 8, 2024 (BUSINESS WIRE) – Neurotech Pharmaceuticals, Inc., an innovator in sustained...
Phase 3 Trial Currently Enrolling MacTel Patients
Neurotech Pharmaceuticals, with support from the Lowy Medical Research Institute, is currently enrolling a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2. This is a multi-center trial...